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Abstract
Background: Examination of host cell-based inhibitors of HIV-1 transcription may be important
for attenuating viral replication. We describe properties of a cellular double-stranded RNA binding
protein with intrinsic affinity for HIV-1 TAR RNA that interferes with Tat/TAR interaction and
inhibits viral gene expression.
Results: Utilizing TAR affinity fractionation, North-Western blotting, and mobility-shift assays, we
show that the C-terminal variant of nuclear factor 90 (NF90ctv) with strong affinity for the TAR
RNA, competes with Tat/TAR interaction in vitro. Analysis of the effect of NF90ctv-TAR RNA
interaction  in vivo showed significant inhibition of Tat-transactivation of HIV-1 LTR in cells
expressing NF90ctv, as well as changes in histone H3 lysine-4 and lysine-9 methylation of HIV
chromatin that are consistent with the epigenetic changes in transcriptionally repressed gene.
Conclusion: Structural integrity of the TAR element is crucial in HIV-1 gene expression. Our
results show that perturbation Tat/TAR RNA interaction by the dsRNA binding protein is sufficient
to inhibit transcriptional activation of HIV-1.
Background
Highly Active Antiretroviral Therapy (HAART) adminis-
tration utilizes a combination of inhibitors of viral pro-
tease and reverse transcriptase to markedly reduce
circulating viral levels [1,2]. However, the emergence of
drug-resistant variants eventually limits the benefits of
chemotherapy; hence the need for alternate or comple-
mentary strategies.
The nascent transcripts from HIV-1 Long Terminal Repeat
(LTR) contain a unique structured RNA domain within
the 5'-nontranslated region known as the transactivation
response (TAR) element which is critical for efficient tran-
scription of viral promoter in response to Tat [3,4]. The
TAR RNA element extends between nucleotides +1 and
+59 and forms a stable RNA stem-loop structure [5,6].
Studies on the transactivation mechanism involving the
Tat-TAR interaction have yielded significant insights into
the regulation of viral gene expression [7-10]. The primary
role of Tat may in fact be to promote assembly of pre-ini-
tiation complex, thereby promoting both transcription
initiation and elongation of HIV-1 promoter [4]. It is
likely therefore, that Tat facilitates chromatin modifica-
tions, thereby promoting initiation and transcription
Published: 12 June 2007
Retrovirology 2007, 4:41 doi:10.1186/1742-4690-4-41
Received: 19 January 2007
Accepted: 12 June 2007
This article is available from: http://www.retrovirology.com/content/4/1/41
© 2007 Agbottah et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
Page 2 of 10
(page number not for citation purposes)
elongation in a series of sequential, coordinated events
that lead to high levels of HIV transcription [11]. Consist-
ent with this view, we noted that Tat/TAR-specified CDK9
(P-TEFb) kinase activity is critical for the phosphorylation
of RNAP II, transcription elongation factors SPT5 and Tat-
SF1 and the induction histone H3 lysine 4 and lysine 36
methylations during transcriptional activation of inte-
grated HIV-1 chromatin [12]. We reasoned therefore that
competition of Tat/TAR interaction by dsRNA binding
protein, such as NF90ctv, might interfere with viral gene
expression in vivo. Given the functional importance of Tat-
TAR interaction in viral life cycle; Tat protein and the TAR
element both present attractive targets for therapeutic
drug design.
Agents affecting the Tat/TAR interaction could prevent
transcriptional activation of HIV-1 genome either by steric
hindrance, a shear displacement mechanism, or by depri-
vation of Tat-cofactor molecules (i.e. CBP/300, Tat-SF1)
[13,14]. The inhibitors of Tat/TAR axis include TAR RNA
decoys [15,16], small molecule inhibitors and ribozyme
[17-24]. Other Tat inhibitors that directly compete with
Tat function include anti-Tat monoclonal antibody and
single-chain anti-Tat antibodies [25-29].
NF90ctv is a C-terminal variant [30] of the NF90 double-
stranded RNA (dsRNA)-binding protein which was origi-
nally reported as a putative transcription factor recogniz-
ing the antigen receptor response element (ARE) in the IL-
2 gene regulatory region [31]. A shared feature of the
dsRNA binding proteins is their conserved N-terminal
domains and the C-terminal dsRNA binding motifs [32].
This motif is well conserved through evolution and inter-
acts with dsRNAs as well as structured RNAs such as the
adenovirus VA RNA II [33]. NF90 has two dsRNA binding
motifs, a putative nuclear localization signal (NLS), and a
leucine-rich nuclear export signal (NES). The C-terminal
portion of NF90 contains an arginine, glycine-rich (RGG)
domain, similar to the motifs which mediate RNA bind-
ing by hnRNP-U and nucleolin [34].
We studied the unique C-terminal variant of NF90
(NF90ctv), where the C-terminal 70 amino acids of
arginine/glycine rich domain is substituted largely by
acidic residues due to a CT insertion in exon 15 that alters
the translational reading frame. Cells expressing NF90ctv
stimulate a transcriptional program of IFN response genes
which is responsible in part for their ability to inhibit
HIV-1 replication [30]. NF90ctv (670a.a) differs from the
related proteins, NF90a (702a.a) and NF90b (706a.a).
Mathews and colleagues analyzed the dsRNA binding
properties of NF90 family of proteins and suggest that
NF90ctv displays ten fold higher affinity for dsRNA as
compared with the normal C-terminal domain RG-rich
proteins of NF90 family [33]. We examined the TAR RNA
binding properties of NF90ctv and show that it attenuates
HIV-1 replication in part by inhibition of Tat-mediated
transactivation of HIV-1 LTR.
Experimental procedures
Plasmids
Recombinant plasmids for expression in mammalian cells
were constructed as follows: pJK2 (HIV-1LTR/β-galactosi-
dase reporter), pSV2-Tat72, (SV40 promoter driven vector
encoding the 72 amino acid first exon of Tat), pCMV-
NF90ctv (CMV promoter driven construct of original
NF90ctv expression vector was supplied by Dr. Peter Kao,
Stanford University CA) [31]. pOZ (bicistronic vector)
and pOZNF90ctv (POZ vector expressing NF90ctv used in
stable cell creation as described below).
Tissue culture and HIV-1 infection
GHOST(3)CXCR4 cells were obtained from the NIH AIDS
Research and Reference Program. The cell line is derived
from human osteosarcoma (HOS) cells by stable trans-
duction with HIV-2 long terminal repeat (LTR)-driven
green fluorescent protein (GFP) reporter, human CD4
receptor, and human CXCR4 chemokine receptor genes.
To generate cell lines stably expressing NF90ctv,
GHOST(3)CXCR4 cells were transduced with
pOZNF90ctv or the plasmid with 'empty vector', using
transduction and selection protocols described elsewhere
[30]. For HIV-1 infection, T-tropic HIV-1 strain NL4-3 was
obtained from the NIH AIDS Research and Reference Pro-
gram. Virus infection was performed by incubating the
cells with HIV-1 NL4-3 (at approximately 5 ng of p24 gag
antigen per 106 cells) in 0.5 ml culture medium supple-
mented with 20 µg/ml polybrene. An aliquot of the cul-
ture supernatant was collected and stored at -80°C.
Production of p24 antigen was analyzed by enzyme-
linked immunosorbent assay (ELISA) according to the
manufacturer's instructions (Beckman Coulter, Fullerton
CA.).
Purification and characterization of TAR binding protein NF90
The purification and characterization of NF90ctv binding
to TAR RNA was examined by stepwise fractionation of
HeLa nuclear extract. The SP Sepharose chromatography
fractions eluted at 0.25 M and 0.5 M NaCl were applied to
a TAR affinity column. Briefly, 200–250 µg of biotinylated
TAR RNA was bound to NutrAvidin Plus beads (Pierce,
Rockville, IL). Binding of RNA to affinity beads packed in
a 0.8 × 7.0 cm column occurred for 30 minutes at 4°C
with rocking. The SP Sepharose pool was applied to the
column, recycled four times and the TAR RNA bound frac-
tions were recovered with a 2.0 M KCl step elution. Pro-
teins contained in the partially purified TAR fraction were
analyzed by SDS-PAGE and North-Western blots [37].Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
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Electrophoretic mobility shift assays (EMSA) with
labeled TAR RNA revealed that the SP Sepharose and the
TAR RNA bound fractions were able to retard TAR RNA
mobility in non-denaturing acrylamide gels.
Competition analysis and RNA binding specificity
500 ng of protein from the TAR RNA purification step was
incubated with 0.2 pmoles of radiolabeled TAR RNA.
Competition for radiolabeled TAR RNA binding was done
with increasing amounts of unlabeled wild-type TAR RNA
and mutant TAR RNA transcripts TM12, TM18 and TM27.
NorthWestern analysis
Equal amounts of protein (25 µg) from the TAR RNA
bound fraction was transferred to immobilon-P and
blocked for 2 hours in NorthWestern buffer (20 mM
HEPES pH 7.9, 50 m M KCl, 0.5 mM EDTA, 2 mM MgCl2,
0.01% NP40 containing 5% milk). Following a 10 minute
wash, the bound protein fraction was probed with 32P-
labeled TAR RNA (5 × 105 cpm/ml, 400 ng) in the North-
Western buffer containing 0.2% milk and 50 U/mL RNa-
sin for 2 hours. The blots were washed, air dried and
exposed for autoradiography overnight at -70°C. Control
RNA probe included human globin RNA. TAR RNA
bound protein fractions (25 µg) were also monitored by
Western blot analysis and probed with anti-NF90 polyclo-
nal antibody.
Transiently transfected HeLa and Jurkat cells
The effect of NF90ctv on Tat-mediated transactivation of
HIV-1 LTR was assessed in both HeLa and Jurkat cells
using CaCl2/HEPES transfection procedure. Constant (2.5
µg) amount of pHIV-LRT-β gal reporter (LacZ gene under
the control of the HIV-1 LTR) was cotransfected with
increasing amounts of pCMV-NF90ctv (0, 2, 10 µg), or
together with 5 µg of pSV2-Tat72 encoding the 72 amino
acid first exon of Tat. To control for transfection efficiency,
0.2 µg of pCMV-CAT plasmid DNA was cotransfected. The
final total amount of DNA in each reaction was adjusted
with salmon sperm DNA. After 48 hours, cell extracts were
prepared and standardized for total protein using a mod-
ified Bradford assay (Bio-Rad). Colorimetric β-galactosi-
dase and CAT assays were performed as described [37]. In
each case β-galactosidase reporter was normalized to pro-
tein concentration based on CAT values used as transfec-
tion control.
Northern blot
Total RNA was isolated from cells using RNAZOL (TEL-
TEST, TX USA). Briefly, 20 × 106 of non-infected or HIV-
1pNL4-3 or pseudotyped VSVG-HIV-1 infected GHOST-
CXCR4/pOZ-NF90 or GHOST-CXCR4/pOZ empty-vector
transduced cells were washed twice with PBS and lysed in
culture flask by addition of 5 ml of RNAZOL. Following
extraction with 0.5 ml chloroform, the RNA was precipi-
tated with isopropanol and washed with 75% Ethanol. 15
µg of total RNA were loaded into each lane of 1% Formal-
dehyde-agarose gel and electrophoresed under standard
conditions. The RNA was transferred to Nitrocellulose
membrane (Schleider & Schuell, Keene, NH) by capillary
action using 10 × SSC and cross-linked using ultraviolet
light. Membranes were prehydrated in 6 × SSC, 1% SDS
solution containing 150 µg of salmon sperm DNA for 2
hours at 65°C. The pre-incubated blots were hybridized at
65°C in shaking water bath for approximately 20 hours
with 32P-random prime labeled DNA fragment of whole
HIV genome (Lofstrand, Gaithersburg, MD). Membranes
were washed twice (5 minutes each in 1 × SSC 1% SDS at
room temperature), at 15 minutes each in 1 × SSC, 10%
SDS at 37°C and finally for 1 hour at 0.1 × SSC 1% SDS at
65°C. The blots were wrapped in Saran wrap and the radi-
oactive bands were detected (Molecular Dynamics, Sun-
nyvale, CA). To control for RNA loading, levels of 18S and
28S or β-actin RNA were used as reference.
Competition of TAR/TAR complex with NF90c protein
One microgram of purified biotin-labeled TAR RNA was
mixed with one microgram (1 µg) of purified Tat protein
for 10 minutes on ice. Next, 100 µl of 30% strepavidin-
sepharose beads in binding buffer (50 mM Tris-HCl, pH
7.8; 5 mM DTT, 100 µg of BSA, 60 mM KCl and 5 mM
MgCl2) were added to the reaction for a final volume of
200 µl. The TAR/Tat complex was incubated with beads
for an additional 1 hr on ice. Next, various concentrations
of purified NF90ctv protein (0.1, 1, and 5 µg) were added
to the mixture. All samples were further incubated on ice
for an additional hour. Finally, samples were centrifuged
at 4°c for 5 minutes, and washed (3X) with TNE300 + 0.1%
NP-40 (50 mM Tris-HCl, pH  7.8, 300 mM NaCl, 1 mM
ETDA, plus 0.1% NP-40). A final wash with TNE50 + 0.1%
NP-40 was performed. Bound complexes were separated
on a 4–20% SDS/PAGE and Western blotted either with
anti-Tat mAb or anti-NF90c antibodies. The same Blot was
cut in half for either Tat or NF90c Western blot.
ChIP assays in OM10.1 cells
OM10.1 cells, a promyelocytic line containing transcrip-
tionally latent, single copy of wild-type HIV-1 integrated
proviral DNA (subtype B, LAI strain) [38], were induced
with TNF-α, either without or following transfection with
the NF90ctv expression plasmid. Approximately 5 × 107
OM10.1 cells were induced with TNF-α (10 ng/ml) for 2
hrs and cross-linked (1% formaldehyde, 10 min at 37°C),
and samples were sonicated to reduce DNA fragments to
~200 to 800 bp for ChIP assays essentially as described
earlier [12]. DNA bound proteins were immunoprecipi-
tated with approximately 10 µg of antibodies indicated in
the figure legends. Specific DNA sequences in the immu-
noprecipitates were detected by PCR using primers spe-Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
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cific for HIV-1 LTR (-92 to +180) and Env (+8440 to
+8791) regions.
Results
Isolation and identification of HIV-1 TAR binding proteins
To detect proteins that interact with the TAR region of
HIV-1 LTR, a three-step purification process was devised
to fractionate nuclear proteins from HeLa cells, including
a Sulpho-phosphate Sepharose (SP Sepharose) chroma-
tography step followed by TAR RNA affinity chromatogra-
phy. The final fraction, a 2.0 M KCl eluate (TAR affinity
fraction) contained proteins p160, p110, p90, and p62.
To determine which proteins from the TAR affinity frac-
tion directly interacted with TAR RNA, North-Western
analysis was performed using radio-labeled TAR RNA,
with beta-globin RNA as a control. The identity of the 90
kDa band was confirmed by Western blotting using anti-
NF90 polyclonal antibody and further established
through N- terminal sequence analysis. As described (Fig-
ure 1), specificity of NF90ctv binding to the TAR RNA was
assessed using selected TAR RNA mutants (TM12, TM18
and TM27; Figure 1A), non- specific dsRNA, poly-IC (data
not shown), and by competition reactions (with unla-
beled TAR RNA mutants incubated with radiolabeled
wild-type TAR RNA; Figure 1B).
Figure 2a shows two proteins, 110 kDa and 90 kDa, that
specifically recognized by TAR RNA in North-Western
blots. As controls we utilized human beta-globin RNA
probes in North-Western blotting that showed no p110 or
p90 bands (data not shown). The results suggested spe-
cific affinity of p110 and p90 to the TAR RNA. We used
equal amounts (25 µg) of protein from each of the purifi-
cation steps in the North-Western assay that were probed
with radio-labeled TAR RNA (Figure 2b). Based on the fact
that a similar protein input from each fractionation step
was used for binding to TAR RNA probe, we estimated (as
judged by densitometer analysis, Figure 2a), that the
intensity of TAR RNA recognition for p90 was approxi-
mately 20-fold higher than the recognition of p110. The
p110 protein is an alternatively spliced form of a family of
double stranded RNA (dsRNA) binding proteins that
includes nuclear factor 90 (NF90) [32]. Two isoforms of
p110 have been identified, NF110a (894a.a) and NF110b
(898a.a). These dsRNA binding proteins are identical at
their N-terminus and have distinct C termini as a result of
alternate splicing [32,33]. The enrichment of the 90 kDa
protein bound to TAR RNA was further ascertained by
Western blotting with NF90 polyclonal antibody (Figure
2b). Sequencing of the N-terminal amino acids of 90 kDa
protein and comparison with the protein data bank con-
firmed its identity to NF90 sequence reported by Corthesy
and Kao [31]. All subsequent assays of the TAR RNA bind-
ing were carried out with NF90 protein expressed with the
cDNA vector (courtesy of Dr. Peter Kao).
Determination of NF90 binding site on the TAR RNA
As the interaction of proteins with the TAR RNA is likely
to be dependent on the RNA structure, in addition to the
recognition of the linear sequence motifs, we investigated
the possible binding site of NF90ctv to TAR RNA using
structural mutants of TAR RNA, and competition with
unlabeled RNAs. The secondary structures and free ener-
gies of the mutant TAR RNA were predicted with an RNA-
folding program [39]. The TAR RNA mutants included
base substitutions and deletions of the TAR domain as
indicated in Figure 1A. Competition reactions were car-
ried out with increasing concentrations of unlabeled
mutant TAR RNAs in the presence of constant amount of
radio-labeled "wild type" TAR RNA. The competition of
TAR RNA-NF90ctv protein complex was assessed on the
basis of the ribonucleoprotein (RNP) complexes formed
Competition Analysis of RNA Binding Specificity Figure 1
Competition Analysis of RNA Binding Specificity. A: 
The structure of the wild type TAR RNA and the TAR 
mutants used in this assay are illustrated. B: 500 ng of pro-
tein from the TAR Fraction containing NF90 was incubated 
with 0.2 pmole radiolabeled TAR RNA (lanes 2, 6, 10, 14, 
18). Competition for radiolabeled TAR RNA binding was 
done with increasing amounts of unlabeled TAR RNA (lanes 
3, 5), TM12 RNA (lanes 7, 9), TM18 RNA (lanes 11–13), 
TM27 RNA (lanes 15–17), or TM12+TM27 RNAs (lanes 19–
21). Samples were run on a 10%PAGE.Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
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in the gel mobility shift assays, utilizing non-denaturing
polyacrylamide gel electrophoresis.
The TAR RNA mutant, TM18, represents an "antisense"
TAR with major alterations in the primary sequence of
stem I, II, III, and IV, while retaining the secondary struc-
ture of wild type TAR RNA (Figure 1A). When TM18 was
used to compete with the RNP complex, free labeled TAR
RNA probe was released at 50 pmols, whereas at 10 pmols
of unlabeled TAR TM18 there is only a partial competition
(Figure 1B lanes 11–13). Thus, NF90ctv appears to have
an affinity for the double stranded stem-loop structure of
the RNA target that is not dependent on the primary
sequence.
To determine whether full length TAR RNA was required
for NF90ctv binding or segments of the TAR RNA structure
are sufficient, we utilized deletion mutants of HIV-1 LTR.
The TAR mutant TM12 contained the lower TAR stem
regions I and II and the loop sequence from the wild type
TAR (Figure 1A). Results showed that TM12 was not able
to compete with wild-type TAR RNA binding to NF90
(Figure 1B lanes 7–9). The TAR mutant, TM27, represent-
ing the upper stem regions III and IV and the loop domain
of the wild type TAR RNA was partially able to compete
TAR RNA binding to NF90ctv (Figure 1B lanes 15–17).
Results of the competition experiment that utilized both
TM12 and TM27 TAR mutants suggested that the 'two
halves' of TAR RNA were not able to compete for NF90
binding (lanes 19–21; compare each competition using
mutant TAR RNAs by the competition with wild-type TAR
RNA, lanes 3–5). These observations suggest that binding
to NF90ctv to HIV-1 TAR RNA requires full length TAR
RNA structure with only partial dependence on primary
sequence (compare lanes 3–5, showing competition with
the wild-type TAR RNA, and lanes 11–13 showing compe-
tition with the 'antisense' mutant TAR RNA, TM18).
Inhibition of Tat-mediated transactivation of HIV-1 LTR 
by NF90
We initially examined the effect of NF90ctv on basal (Tat-
independent) HIV-1 transcription in HeLa cells by trans-
fecting (2.5 µg) of pHIV-LTR/β-galactosidase reporter
plasmid, and increasing amounts (0.0, 2, or 10.0 µg) of
pCMV-NF90ctv per 5 × 106 cells using CaCl2/Hepes pre-
cipitation method (Figure 3, left panel). The effect of
NF90ctv on transcription activation was analyzed by add-
ing constant amount (5 µg) of pSV2-Tat72 and increasing
amounts of NF90ctv plasmid (Figure 3, right panel).
Transfection efficiency was normalized by co-transfection
with pCMVCAT. In each case the total amount of DNA
transfected was kept constant by addition of sonicated
salmon sperm DNA. Results indicate that NF90ctv does
not exert a noticeable effect on basal (Tat-independent)
transcription levels (Fig. 3, left panel). Cells co-transfected
with NF90ctv and pSV2-Tat72 displayed a significant
decrease in Tat-transactivation levels. Cells that received
only the Tat construct displayed over 70-fold induction of
the β-galactosidase reporter. Tat transactivation was sig-
nificantly reduced by increasing NF90ctv expression in
HeLa cells (Figure 3, right panel).
NF90ctv reduces HIV-1 RNA levels
To assess whether NF90ctv affects HIV-1 transcripts in
vivo, we analyzed RNA isolated from HIV-1 infected cells
that were stably transduced with NF90ctv expressing vec-
tor as compared with control cells transduced with the
empty vector [30]. Northern blot assays were carried out
on total cell RNA isolated from the GHOST-CXCR-4 cells
infected either with HIV-1 PNL4-3 or HIV-1 pseudotyped
with vesicular stomatitis virus G protein (HIV-VSVG) to
analyze the effect of NF90ctv in single-round infection.
NF90ctv expression was monitored by Western blot using
both polyclonal anti-NF90 antibody as well as anti-FLAG
monoclonal antibody. Virus production was monitored
by measurement of p24 levels in the culture media by
enzyme-linked immunosorbent assay (ELISA) (Beckman-
Coulter, California). Twenty micrograms (20 µg) of total
cell RNA was resolved on a 1% agarose-formaldehyde gel
and probed with 32p-labeled HIV-1 probe. Comparison
of lanes 3 and 5 in Fig. 4 shows NF90ctv inhibition of viral
transcripts in cells infected with T-tropic HIV-1 NL4-3.
The level of inhibition of the 9.0 Kb full length RNA was
higher (5 fold) than that of the 4.0 Kb (3 fold), partially
spliced transcripts. The doubly spliced, 2 kb RNA tran-
scripts appeared to be minimally represented in both
cells. The results could also be explained if NF90ctv also
blocks cellular splicing machinery or promotes mRNA
decay. Viral RNA from ACH2 cells (T-cells latently
Identification of NF90 as HIV-1TAR binding protein Figure 2
Identification of NF90 as HIV-1TAR binding protein. 
a: Autoradiogram of a NorthWestern blot in which 25ug of 
HeLa cell nuclear protein from each purification step was 
probed with 7.5 × 106 cpm of radiolabeled TAR RNA for 2 
hours, washed, and exposed to autoradiographic film for 2 
hours. b: Immobilon-P transferred proteins were probed 
with polyclonal anti-NF90 at 1 ug/mL.Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
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infected with HIV-1 that could be induced with sodium
butyrate [40] was used as an internal marker (Fig 4A, lane
1). In the case of single cycle infection with pseudotyped
VSVG-HIV, both the 9.0 Kb and the 4.0 Kb transcripts
were markedly inhibited in the presence of NF90ctv
(about 8-fold inhibition of both the 9.0 kb and 4.0 kb
transcripts, Figure 4A lanes 6 and 7). Figure 4B shows
Northern blot of the same gel probed with [32p]-labeled
β-actin to illustrate the equivalent amount of total RNA in
each lane. Ethidium bromide stained gel of the RNA sam-
ples is illustrated (Fig 4C).
NF90ctv competes with Tat for TAR RNA binding
We next asked whether NF90ctv could effectively compete
with Tat for TAR RNA binding. To do this, we designed a
competition experiment where biotinylated wild type TAR
RNA was mixed with Tat protein for 10 minutes and then
increasing concentration of purified NF90ctv protein was
added to the mixture. The resulting complex was then
washed and bound proteins were resolved by 4–20%
SDS/PAGE, and Western blotted with either anti-Tat or
anti-NF90ctv antibody. Results of such an experiment is
shown in Figure 5, where wild type Tat specifically bound
to TAR RNA and the binding could be competed with
excess wild type but not mutant TAR (TM26; compare
lanes 4, 5, upper panel). The TAR mutant, TM26 has base
NF90ctv impacts HIV-1 replication at the transcription level Figure 4
NF90ctv impacts HIV-1 replication at the transcrip-
tion level. Total cell RNA extracted from NF90ctv express-
ing cells (pOZNF90, lanes 4,5) or control cells transduced 
with empty vector (pOZ, lanes 2,3) infected with HIV-
1pNL4-3 or pseudotyped VSVG-HIV-1 for single round infec-
tion (lanes 6,7), was fractionated on a 1% forlmadehyde-agar-
ose gel and probed with [32p]-labeled HIV-1LTR probe. 
Shown in Figure 4A is a Northern blot of HIV-1 p NL4-3 and 
VSVG-HIV infected and non-infected cells (designated as plus 
(+) or minus (-) respectively. Lane 1 is positive control HIV 
RNA from ACH2 cells. Figure 4B shows the same gel probed 
with β-actin. Figure 4C illustrates the ethidium bromide-
stained gel shown in Figure 4A and 4B.
NF90 inhibits Tat- trans-activation in concentration-depend- ent manner Figure 3
NF90 inhibits Tat- trans-activation in concentration-
dependent manner. The effect of NF90ctv on basal and 
Tat-mediated transactivation of HIV-1 LTR was assessed in 
both HeLa and Jurkat cells using CaCl2/Hepes transfection as 
follow. Duplicate 6 well- plates of HeLa cells received 2.5 ug 
of pHIV-β gal per 5 × 106 cells and increasing amounts (0.0 
ug, 2.0 ug or 10.0 ug) of pCMV-NF90ctv. One set of plate 
(Transactivation received constant amounts (5.0 ug) of pSV2-
Tat72. In each assay, 0.2 µg of pCMVCAT was cotransfected 
to monitor transfection efficiency. Following the transfection, 
cell extracts were prepared and standardized for total pro-
tein; colorimetric β-galactosidase and CAT assays were per-
formed as before [37).Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
Page 7 of 10
(page number not for citation purposes)
substitutions of the Tat-binding pyrimidine bulge region
and the cyclin T1 binding loop domain of TAR RNA [36].
However, when increasing concentrations (0.1, 1, 5 µg) of
purified NF90ctv protein was added to the complex, Tat-
TAR RNA complex was displaced with NF90ctv (Lanes 6–
8, upper panel). These results imply that Tat bound to the
TAR RNA may be displaced by NF90ctv, thus allowing
NF90ctv to interfere with HIV-1 expression.
Interference of Tat-transactivation by TAR RNA-NF90ctv 
binding results in histone methylation of HIV chromatin
We previously reported that transcriptional activation of
latent proviral DNA by TNF-α induction of OM10.1 cells,
a promyelocytic cell line that contains single copy inte-
grated proviral DNA, is mediated by Tat [12]. It was of
interest therefore to ask if the interference of Tat-transacti-
vation by NF90ctv would result in inhibition of transcrip-
tional activation of HIV-1 LTR. To approach the issue we
analyzed the methylation of histone H3K4 and H3K9 in
HIV-1 chromatin by chromatin-immunoprecipitation
(ChIP) assays in latent and TNF-α induced OM10.1 cells,
and compared the HIV-1 chromatin modification in nor-
mal and NF90ctv transfected OM10.1 cells. The results of
ChIP assays (Figure 6) make several points: (i) histone
H3K4me3 levels (compare Fig.6, lanes 5, 10 and 15)
clearly show a marked induction of H3K4me3 upon tran-
scriptional stimulation of latent HIV-1 LTR. However, in
NF90ctv transfected OM10.1 cells, there is only minimal
induction of H3K4 methylation, even after TNFα induc-
tion (compare LTR lanes 10 and 15). Considering that
H3K4 methylation marks active genes [41], the results
suggest that competition of Tat/TAR RNA interaction by
NF90ctv protein results in inhibition of HIV gene expres-
sion.
Among the epigenetic marks of transcriptionally silenced
chromatin, histone H3K9 methylation, and in particular
different degrees of H3K9 methylation suggest regulated
suppression of transcriptionally active chromatin [42].
Histone lysine-9 trimethyl (H3K9me3) state in particular,
is regarded as a more robust signal of long-term epigenetic
memory. We next determined the levels of mono-, di-, or
tri-methyl H3K9 in HIV chromatin in the inactive, TNF-α
induced and NF90ctv expressing TNFα induced OM10.1
Competition of Tat/TAR interaction by NF90ctv interferes  with HIV-1 chromatin activation Figure 6
Competition of Tat/TAR interaction by NF90ctv 
interferes with HIV-1 chromatin activation: Changes in 
Histone H3 K4 and H3K9 methylation were measured by 
ChIP assays in integrated HIV-1 chromatin in OM10.1 cells. 
Comparison of H3Kme3 in uninduced (lane, 5) and TNF-α 
induced cells (lane, 10) shows marks of transcriptional activa-
tion of HIV-1 chromatin. In cells expressing NF90ctv how-
ever, the H3K4me3 methylation, a mark of transcriptionally 
active gene is inhibited (lane 15). Lanes 1, 6, and 11 represent 
IP controls. The empty vector (pCI-neo) was used as trans-
fection control for NF90ctv transfected OM10.1 cells (lanes 
11–15). H3K9 methylations (lanes 2–4, 7–9 and 12–14) show 
a reduction in TNF-α induced cells (compare lanes 2–4 and 
7–9). Note the lack of inhibition of H3K9 methylation (lanes 
4, 9, and 14) in TNF-α induced cells in the presence of 
NF90ctv (lane 14), suggesting a long-term memory of tran-
scriptional inhibition in NF90ctv expressing cells.
Competition of TAR/TAR complex formation by NF90c pro- tein Figure 5
Competition of TAR/TAR complex formation by 
NF90c protein. One microgram of purified biotin-labeled 
TAR RNA was mixed with one microgram of purified Tat 
protein for 10 minutes on ice. Next, 100 µl of 30% strepavi-
din sepharose beads in binding buffer (50 mM Tris-HCl, 
pH7.8; 5 mM DTT, 100 µg of BSA, 60 mM KCl and 5 mM 
MgCl2) were added to the reaction for a final volume of 200 
µl. The TAR/Tat complex was incubated with beads for an 
additional 1 hr on ice. Next, purified NF90c at various con-
centrations (0.1, 1, and 5 µg) were added to the mixture. All 
samples were further incubated on ice for additional one 
hour. Finally, samples were centrifuged at 4°c for 5 minutes, 
and washed (3×) with TNE300 + 0.1% NP-40 (50 mM Tris-
HCl, pH7.8, 300 mM NaCl, 1 mM ETDA, plus 0.1% NP-40). 
A final wash was with TNE50 + 0.1% NP-40 was performed. 
Bound complexes were separated on a 4–20% SDS/PAGE 
and western blotted with anti-Tat mAb or anti-NF90c anti-
bodies. Same Blot was cut in half for either Tat or NF90c 
western blot. Lane 1: 14C protein molecular weight marker, 
Lane 2 is with no Tat, Lane 3 with Tat, Lane 4 and 5 are with 
addition of five microgram of either wild type TAR or a 
mutant TAR RNA (TM26) as specific and non-specific com-
petitors, respectively. Lanes 6–8 represent addition of puri-
fied NF90ctv protein in presence of constant amount of Tat.Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
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cells. As is shown in Figure 6 (compare lanes 2–4 with
lanes 7–9), there is relative decline in H3K9me1,
H3K9me2 and H3K9me3 as the HIV chromatin is tran-
scriptionally induced. In TNF-α induced OM10.1 cells
which are also transduced with NF90ctv expression plas-
mid (lanes 12–14), there is a relative induction of
H3K9me3 (Fig.6, compare lanes 12, 13 with lane 14). The
results suggest that interference of Tat-transactivation of
HIV-1 due to the competition of Tat/TAR interaction by
NF90ctv results in long-term inhibitory epigenetic mem-
ory [42]. The results, however, do not suggest a direct role
of NF90ctv in epigenetic modifications of HIV-1 chroma-
tin. Rather, the data suggest an indirect role of NF90ctv-
mediated interference of Tat/TAR interaction that leads to
the transcriptional repression.
Discussion
Eukaryotic cells depend on recognizable RNA secondary
structures for a variety of normal cellular pathways. Cellu-
lar RNA-binding proteins appear to function as informa-
tion sensors, extracting the information content from
specific RNA structural domains to initiate downstream
signaling that translate analog to digital information [57].
Significant examples of such RNA structure-directed sign-
aling include viral RNA-mediated activation of innate
antiviral defense [reviewed in [54]]. It has been speculated
that mammalian cells employ RNA interference (RNAi)
pathway as an antiviral mechanism. The HIV-1 TAR RNA
binding protein (TRBP) has an essential role in HIV repli-
cation as well as in RNAi response where it mediates the
association of Dicer with siRNA and Ago2 in RISC com-
plex [reviewed in [55]]. Viruses display clear tissue tro-
pism, suggesting that cellular microRNA (miRNA)
regulated genes could modulate viral pathogenesis.
Recent studies showing regulation of HIV-1 replication by
the miRNA modulated host proteins (which are essential
for virus replication), further supports the importance of
RNAi-mediated antiviral defense [reviewed in [56]]. Rec-
ognition and information extraction for downstream sig-
naling of specific structural domains in RNA may define
the outcome of the viral-host interaction.
In the present study we utilized a C-terminal variant of the
cellular RNA-binding protein (NF90ctv) that was initially
isolated by HIV-1 TAR RNA affinity fractionation. We
focused on the C-terminal variant of NF90 to further
explore its mechanism of action as a potential antiviral
target protein. In an earlier report [30], we described that
CD4/CXCR4 positive human osteosarcoma cells stably
expressing NF90ctv were able to induce transcriptional
program of antiviral response genes to block HIV-1 repli-
cation. We recently reported [43] that co-expression of
NF90ctv competes with HIV-1 Rev-RRE interaction and
may contribute to antiviral response. In the present study
we extended the analysis viral RNA-NF90ctv interaction to
ask whether NF90ctv binding to HIV TAR RNA competes
with Tat-TAR RNA interaction and attenuates of HIV-1
replication. These studies allow us to examine the infor-
mation 'coded' in the TAR RNA structure, as the basis of
recognition by the host protein, and the impact of these
interactions on viral replication. Specifically, we used
NF90ctv to target sites on the TAR RNA, to disrupt viral
processes that require unimpeded access to TAR RNA.
The idea that TAR may be a novel target for drug interven-
tion is supported by the fact that any natural or induced
mutation that destabilizes the TAR structure disrupts base
pairing in the TAR stem region [44]. Also loss of TAR spe-
cific secondary structure abolishes Tat-stimulated tran-
scription resulting in premature transcription termination
at random locations downstream of the viral RNA start
site [44,45].
NF90 and NF45 are subunits of a heterodimeric protein
originally isolated as a putative transcription factor
thought to bind to the antigen receptor response elements
(ARRE) of the IL-2 gene promoter [31]. Interestingly, sub-
sequent studies have characterized NF90 interactions with
RNA species such as the IL2 mRNA [46], the Tau mRNA in
neurons [47], and the ADAR1 RNA editing complex [48].
NF90's recognition of these RNA species depends on sec-
ondary structure, rather than primary sequence; our stud-
ies show that NF90 recognition of RNA species depends
on somewhat constrained structural parameters.
NF90 protein has two dsRNA binding domains as well as
a putative nuclear localization signal (NLS), a leucine-rich
nuclear export signal (NES) and a C-terminal domain that
is arginine, glycine (RG) rich [33]. In quiescent Jurkat
cells, NF90 is predominantly localized in the nucleus,
however, in response to activation signals there is an
increase in its cytoplasmic translocation. Increased cyto-
plasmic abundance of NF90 depends on the presence of
its nuclear export sequence (NES) [46]. The NF90 cDNA
originally reported [31], and used in this work is a poly-
morphic C-terminal variant (NF90ctv), which results
from a dinucleotide (CT) insertion that results in transla-
tion frame-shift giving rise to a protein with a shorter C
terminus lacking both the RGG and GQSY domains [35].
As we reported earlier [30], real-time quantitative RT-PCR
analysis suggests that the endogenous levels of NF90ctv
are undetectable in cell lines we studied; levels of the
NF90 C-terminal variants in human primary cells is not
known.
Reichman and Mathews [33] analyzed the RNA binding
properties of NF90 family of dsRNA binding proteins and
suggest that the NF90ctv isoform (lacking the RGD and
GQSY domains) has tenfold higher dsRNA binding prop-
erties. In addition we find that NF90ctv interacts with con-Retrovirology 2007, 4:41 http://www.retrovirology.com/content/4/1/41
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siderable specificity with regions of the structured HIV-1
TAR RNA domain. This was demonstrated by Northwest-
ern blotting and competition assays using TAR-RNA
mutants. Biological effects of NF90ctv, we reasoned, may
in part be due to its affinity for the HIV-1 TAR element
which results in disruption of specific steps in viral repli-
cation cycle that depend upon TAR RNA-host protein
interaction.
Transcription activation by Tat occurs through TAR and
requires proper folding of the TAR RNA hairpin structure
[49]. The role of TAR in regulating HIV-1 gene expression
has been extensively investigated by using in vitro tran-
scription, transient expression analysis and nuclear run-
on experiments [50-53]. Binding of HIV-1 Tat protein to
the TAR RNA structure is critically dependent upon the
positive transcription elongation factor b (P-TEFb), com-
posed of cyclin-dependent kinase 9 (CDK9) and cyclin T1.
We reported that the Tat/TAR-dependent P-TEFb kinase
activity is required for phosphorylation at Ser 2 and Ser 5
of RNAPII C-terminal domain repeats. Importantly, inhi-
bition of the P-TEFb kinase activity reduced methylation
of histone H3 lysine 4 in integrated HIV-1 chromatin [12].
These studies demonstrate that the TAR RNA loop, bulge,
and stem structure are each critical for viral gene expres-
sion. These unique features of the TAR secondary structure
encode information whose downstream signaling is vital
for viral replication. We envisaged that NF90ctv recogni-
tion of the TAR region may provide a potential barrier in
recruitment of Tat and associated cellular factors that
results in down regulation of viral gene transactivation.
We approached the issue by biochemical binding/compe-
tition assays, transcription in vivo as well as by examining
the epigenetic modifications of HIV-1 genome to assess
the consequence of competing Tat/TAR RNA interaction
in the presence of NF90ctv. We utilized pHIV-1 LTR-β gal
and pSV-tat constructs to transfect HeLa cells in the pres-
ence and absence of NF90ctv. The basal level of transcrip-
tion of HIV-1 LTR as judged by β-galactosidase reporter
gene expression was stimulated by Tat. However, addition
of NF90ctv significantly inhibited Tat-mediated transacti-
vation. These results suggest that NF90ctv may effectively
sequester TAR RNA and block Tat-TAR interaction thereby
limiting Tat-mediated transactivation of HIV-1 transcrip-
tion. Importantly, the competition of Tat-TAR RNA inter-
action mediated by NF90ctv leads to epigenetic marks of
transcriptionally silenced HIV-1 chromatin.
Inhibition of the Tat-TAR interaction is considered as a
realistic approach to develop new anti-HIV compounds.
Here we present a novel HIV-1 Tat/TAR antagonist,
NF90ctv which inhibits Tat transactivation and attenuates
viral production. Examining host cell response as a result
of constitutive expression of NF90ctv, Krasnoselskaya-Riz
et al, [30] reported that NF90ctv expressing cells induce
IFN-response genes which in part accounts for the HIV-1
resistance.
In summary, we have identified a novel cellular protein
that is able to bind to the TAR element and suppress Tat-
mediated transcriptional trans-activation of HIV-1 LTR.
NF90ctv recognition of TAR enables it to inhibit specific
steps in the viral life cycle, in parallel with the activation
of innate antiviral defenses of the host.
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